Hypertension-induced end-organ damage: a new transgenic approach to an old problem

FC Luft, E Mervaala, DN Müller, V Gross… - …, 1999 - Am Heart Assoc
FC Luft, E Mervaala, DN Müller, V Gross, F Schmidt, JK Park, C Schmitz, A Lippoldt, V Breu…
Hypertension, 1999Am Heart Assoc
Angiotensin (Ang) II-induced organ damage has fascinated students of hypertension since
the work of Wilson and Byrom. We are investigating a double transgenic rat (dTGR) model,
in which rats transgenic for the human angiotensinogen and renin genes are crossed. These
rats develop moderately severe hypertension but die of end-organ cardiac and renal
damage by week 7. The heart shows necrosis and fibrosis, whereas the kidneys resemble
the hemolytic-uremic syndrome vasculopathy. Surface adhesion molecules (ICAM-1 and …
Abstract
—Angiotensin (Ang) II-induced organ damage has fascinated students of hypertension since the work of Wilson and Byrom. We are investigating a double transgenic rat (dTGR) model, in which rats transgenic for the human angiotensinogen and renin genes are crossed. These rats develop moderately severe hypertension but die of end-organ cardiac and renal damage by week 7. The heart shows necrosis and fibrosis, whereas the kidneys resemble the hemolytic-uremic syndrome vasculopathy. Surface adhesion molecules (ICAM-1 and VCAM-1) are expressed early on the endothelium, while the corresponding ligands are found on circulating leukocytes. Leukocyte infiltration in the vascular wall accompanies PAI-1, MCP-1, and VEGF expression. The expression of TGF-β and deposition of extracellular matrix proteins follows, which is accompanied by fibrinoid vasculitis in small vessels of the heart and kidneys. Angiotensin-converting enzyme inhibitors and AT1 receptor blockers each lowered blood pressure and shifted pressure natriuresis partially leftward by different mechanisms. When combined, they normalized blood pressure, pressure natriuresis, and protected from vasculopathy completely. Renin inhibition lowered blood pressure partially, but protected from vasculopathy completely. Endothelin receptor blockade had no influence on blood pressure but protected from vasculopathy and improved survival. We show evidence that Ang II stimulates oxidative stress directly or indirectly via endothelin 1 and that NFκB is upregulated in this model. We speculate that the transcription factors NFκB and AP-1 are involved with initiating chemokine and cytokine expression, leading to the above cascade. The unique model and our pharmacological probes will enable us to test these hypotheses.
Am Heart Assoc